GlaxoSmithKline puts focus on bringing drugs to market faster
According to Luke Miels, drugs giant GlaxoSmithKline (GSK)’s head of pharmaceuticals, it’s time to take the foot off the break when it comes to getting drugs to market. Miels recently told reporters that the “old days” of “doing one thing at a time” are now gone, and that GSK and other players in the space should funnel money into the most promising developmental routes and fast-track them to market.
GSK’s share price has appreciated by 5% so far this year
Source: Yahoo Finance
In an interview, Miels said: “In the past, 10 programmes were chosen, a budget for eight was allocated. Usually what happened was that time was the trade-off that was made. Now what we do is we pick five or six programmes, and concentrate investment there.” Doing that properly means conducting multiple trials on different groups of people at different facilities around the world – something that GSK rarely had to worry about in the “old days”. Miels explains: “Rather than do things sequentially, you do them in parallel, or as close to parallel as possible.”
GSK is Britain’s biggest drug maker, and a global force in the pharmaceutical industry. But powerful rivals in China and the US remain a threat – GSK is pushing for speed in order to remain competitive. Miels says that this is particularly important in a world where US legislators and medical insurers are taking a tougher stance on drug prices.
And it is also relevant given the rapid growth in the Chinese market, which is spurring a more sophisticated healthcare system. As a result of that system, a number of Chinese biotech groups have emerged that are quickly catching up to established western giants.
Dominion holds GlaxoSmithKline in its Global Trends Managed Fund.
If you would you like to receive the Newsfeeds daily, please click here to sign up now!Help us make this Newsfeed better by rating this article. 1 star = Poor and 5 stars = Excellent
- Click here to print this story: Print
The views expressed in this article are those of the author at the date of publication and not necessarily those of Dominion Fund Management Limited. The content of this article is not intended as investment advice and will not be updated after publication. Images, video, quotations from literature and any such material which may be subject to copyright is reproduced in whole or in part in this article on the basis of Fair use as applied to news reporting and journalistic comment on events.